Sinopharm Capital

  • GenFleet Therapeutics closes RMB400m Series B financing

    GenFleet Therapeutics has secured nearly 400 million yuan in a Series B round of financing jointly led by CDH Investments, and a healthcare industry fund of government-led Shenzhen Capital Group. South China Venture Capital and Panlin Capital participated in the investment. Existing investors, including Sinopharm Capital, Lake Bleu Capital, and HighLight Capital, also invested in this round.